相关实验视频

Updated: Jul 26, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

POTEE突变作为肺腺癌中免疫检查点抑制剂的潜在预测生物标志物

Yongzhao Li¹, Qidong Yang², Yaqin Liu²

¹Center of Treatment of Myasthenia Gravis, Hebei Provincial Key Laboratory of Myasthenia Gravis, Hebei Provincial Clinical Research Center for Myasthenia gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Hebei, 050000, Shijiazhuang, China.

Investigational new drugs

|June 15, 2023

概括

在接受免疫检查点抑制剂 (ICI) 治疗的非小细胞肺癌患者中,POTEE突变预测了更好的结果. 突变POTEE的瘤显示出更高的响应率和更长的无进展生存期,这表明POTEE是潜在的生物标志物.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但患者选择仍然是一个挑战.
POTEE (POTE安基林域家族成员E) 是一种与癌症和免疫治疗相关的灵长类特定基因家族.
确定ICI在非小细胞肺癌 (NSCLC) 疗效的预测生物标志物至关重要.

研究的目的:

调查POTEE基因突变与接受ICI治疗的NSCLC患者的临床结果之间的相关性.
评估POTEE突变作为NSCLC免疫治疗反应的预测生物标志物,特别是肺腺癌 (LUAD).
探索与POTEE突变和ICI治疗相关的分子机制.

主要方法:

合并了三个NSCLC队列 (n=165) 来分析POTEE突变状态和ICI治疗疗效.
利用癌症基因组图谱 (TCGA) 数据库进行预后分析和分子机制探索.
进行了统计分析,包括客观反应率 (ORR),无进展生存率 (PFS),瘤突变负担 (TMB),新抗原负载 (NAL) 和基因组丰富分析 (GSEA).

主要成果:

与POTEE野生型相比,POTEE突变NSCLC患者的ORR显著更高 (100%对27.7%) 和PFS更长 (P=0.001),与POTEE野生型相比.
在LUAD中,POTEE突变也与更高的ORR (100%对27.2%) 和改善的PFS (P=0.001) 相相关.
POTEE突变与更高的TMB和NAL相关,但在LUAD中没有PD-L1表达;GSEA揭示了DNA修复途径的丰富.

结论:

POTEE突变状态是ICI治疗的NSCLC患者良好的临床结果的重要预测因素.
POTEE突变可能成为免疫疗法疗效的有价值的预测生物标志物,特别是在LUAD中.
需要进一步的前性研究来验证这些发现并探索潜在的分子机制.

关键词:

生物标志物生物标志物免疫检查点抑制剂免疫检查点抑制剂肺部腺癌瘤是肺部腺癌.下一代测序 (NGS) 是指下一代的测序.在POTEEE中使用.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...